The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Open accessAbstract
BACKGROUND: Somatic mutations have the potential to encode "non-self" immunogenic antigens. We hypothesized that tumors with a large number of somatic mutations due to mismatch-repair defects may be susceptible to immune checkpoint blockade. METHODS: We conducted a phase 2 study to evaluate the clinical activity of pembrolizumab, an anti-programmed death 1 immune checkpoint inhibitor, in 41 patients with progressive metastatic carcinoma with or without mismatch-repair deficiency. Pembrolizumab was administered intravenously at a dose of 10 mg per kilogram of body weight every 14 days in patients with mismatch repair-deficient colorectal cancers, patients with mismatch repair-proficient colorectal cancers, and patients with mismatch repair-deficient cancers that were not colorectal. The coprimary end points were the immune-related objective response rate and the 20-week immune-related progression-free survival rate. RESULTS: The immune-related objective response rate and immune-related progression-free survival rate were 40% (4 of 10 patients) and 78% (7 of 9 patients), respectively, for mismatch repair-deficient colorectal cancers and 0% (0 of 18 patients) and 11% (2 of 18 patients) for mismatch repair-proficient colorectal cancers. The median progression-free survival and overall survival were not reached in the cohort with mismatch repair-deficient colorectal cancer but were 2.2 and 5.0 months, respectively, in the cohort with mismatch repair-proficient colorectal cancer (hazard ratio for disease progression or death, 0.10 [P<0.001], and hazard ratio for death, 0.22 [P=0.05]). Patients with mismatch repair-deficient noncolorectal cancer had responses similar to those of patients with mismatch repair-deficient colorectal cancer (immune-related objective response rate, 71% [5 of 7 patients]; immune-related progression-free survival rate, 67% [4 of 6 patients]). Whole-exome sequencing revealed a mean of 1782 somatic mutations per tumor in mismatch repair-deficient tumors, as compared with 73 in mismatch repair-proficient tumors (P=0.007), and high somatic mutation loads were associated with prolonged progression-free survival (P=0.02). CONCLUSIONS: This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab. (Funded by Johns Hopkins University and others; ClinicalTrials.gov number, NCT01876511.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A seminal phase II trial from 2015 showed that ICB with the anti-PD-1 antibody pembrolizumab resulted in durable responses in more than 50% of patients with dMMR/MSI-H but not in pMMR/MSS mCRC.100”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [100]
In the citing paper
“This was particularly noted in anti-CTLA-4-treated melanoma patients whose tumors displayed neo-antigens (87) and similarly in anti-PD-1-treated patients with colorectal cancers or non-small cell lung cancers that were mismatch-repair deficient or had high mutation rates, respectively (78, 86).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [78]
In the citing paper
“Anti-PD-1 therapies have also received approval for treatment of patients with cancer who are diagnosed with tumors that have microsatellite instabilityhigh (MSI-H )/mismatch-repair defi ciency (dMMR; refs.47,48 ) or high tumor mutational burden (TMB-high) regardless of tumor type ( 49 ).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [47]
In the citing paper
“An initial study in patients with colorectal cancer demonstrated significantly higher rates of response to pembrolizumab in dMMR patients compared with MMR-proficient patients (47), a finding that was later extended to multiple tumor types (48).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [47]
In the citing paper
“Previous reports have shown that the total number of somatic coding mutations in a cancer genome correlates with response to ICB (7, 8, 10–12, 17).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [8]
In the citing paper
“Response rates to ICI treatment vary widely among different cancers, ranging from greater than 80% in patients with refractory Hodgkin's lymphoma to little or no response in patients with mismatch repair-proficient colorectal cancer (76, 77); many tumor indications fall within a response rate range of 20% to 40% (78).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citation
Flagged first, then by citations
1 of the 59 references couldn’t be matched to a known paper.
Research works printed but not linked: 4
- Eshleman JR, 1995, Oncogene, 10, 33
- Meltzer SJ, 1994, Cancer Res, 54, 3379
- Nakata B, 2002, Clin Cancer Res, 8, 2536
- Kim H, 1994, Am J Pathol, 145, 148
Cited by
Sorted by citations
Items 601–700 of 1,080
Ward, J. P., Gubin, M. M., & Schreiber, R. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2016.01.001 · Cited by 232
González, R. S., Salaria, S. N., Bohannon, C. D., Huber, A. R., Feely, M. M., & Shi, C. (2016) · Histopathology · doi:10.1111/his.13118 · Cited by 228
Kline, C., Joseph, N. M., Grenert, J. P., Ziffle, J. V., Talevich, E., Onodera, C. S., Aboian, M., Cha, S., Raleigh, D. R., Braunstein, S. E., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now254 · Cited by 228
Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment
van Zyl, B., Tang, D., & Bowden, N. A. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0336 · Cited by 234
Konstantinopoulos, P. A., Luo, W., Liu, J. F., Gulhan, D., Krasner, C. N., Ishizuka, J. J., Gockley, A. A., Buss, M. K., Growdon, W. B., Crowe, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01021 · Cited by 228
Genomic Profiling of Small-Bowel Adenocarcinoma
Schrock, A. B., Devoe, C., McWilliams, R. R., Sun, J. X., Aparicio, T., Stephens, P. J., Ross, J. S., Wilson, R. H., Miller, V. A., Ali, S. M., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1051 · Cited by 232
Frankell, A. M., Jammula, S., Li, X., Contino, G., Killcoyne, S., Abbas, S., Perner, J., Bower, L., Devonshire, G., Ococks, E., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0331-5 · Cited by 234
Clinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 241
Ratti, M., Lampis, A., Hahne, J. C., Passalacqua, R., & Valeri, N. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2906-9 · Cited by 233
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells
Limagne, E., Nuttin, L., Thibaudin, M., Jacquin, É., Aucagne, R., Bon, M., Revy, S., Barnestein, R., Ballot, E., Truntzer, C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.12.009 · Cited by 231
Kawazoe, A., Kuwata, T., Kuboki, Y., Shitara, K., Nagatsuma, A. K., Aizawa, M., Yoshino, T., Doi, T., Ohtsu, A., & Ochiai, A. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0631-3 · Cited by 229
Genomic landscape of high-grade meningiomas
Bi, W. L., Greenwald, N. F., Abedalthagafi, M., Wala, J. A., Gibson, W. J., Agarwalla, P. K., Horowitz, P. M., Schumacher, S. E., Esaulova, E., Mei, Y., et al. (2017) · npj Genomic Medicine · doi:10.1038/s41525-017-0014-7 · Cited by 229
Haen, S. P., Loeffler, M. W., Rammensee, H., & Brossart, P. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0387-x · Cited by 241
Wang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683419 · Cited by 224
The influence of subclonal resistance mutations on targeted cancer therapy
Schmitt, M. W., Loeb, L. A., & Salk, J. J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.175 · Cited by 234
Campesato, L. F., Barroso‐Sousa, R., Jimenez, L., Corrêa, B., Sabbaga, J., Hoff, P. M., Reis, L. F. L., Galante, P. A. F., & Camargo, A. A. (2015) · Oncotarget · doi:10.18632/oncotarget.5950 · Cited by 224
Microsatellite instability in colorectal cancer.
de’Angelis, G. L., Bottarelli, L., Azzoni, C., de’Angelis, N., Leandro, G., Mario, F. D., Gaiani, F., & Negri, F. (2018) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v89i9-s.7960 · Cited by 233
Cancer immunotherapy targeting neoantigens
Lu, Y., & Robbins, P. F. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.11.002 · Cited by 225
Trabucco, S. E., Gowen, K. A., Maund, S. L., Sanford, E. M., Fabrizio, D. A., Hall, M. J., Yakirevich, E., Gregg, J. P., Stephens, P. J., Frampton, G. M., et al. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.06.011 · Cited by 229
Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy
Igarashi, Y., & Sasada, T. (2020) · Journal of Immunology Research · doi:10.1155/2020/5825401 · Cited by 226
Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Khaliq, A. M., Erdoğan, C., Kurt, Z., Turgut, S. S., Grunvald, M. W., Rand, T., Khare, S., Borgia, J. A., Hayden, D. M., Pappas, S. G., et al. (2022) · Genome biology · doi:10.1186/s13059-022-02677-z · Cited by 246
Current status of immune checkpoint inhibitors for gastric cancer
Kono, K., Nakajima, S., & Mimura, K. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01090-4 · Cited by 226
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Boyiadzis, M. M., Kirkwood, J. M., Marshall, J. L., Pritchard, C. C., Azad, N. S., & Gulley, J. L. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0342-x · Cited by 219
Self-citationCaswell, D. R., & Swanton, C. (2017) · BMC Medicine · doi:10.1186/s12916-017-0900-y · Cited by 225
Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers
Salem, M. E., Weinberg, B. A., Xiu, J., El‐Deiry, W. S., Hwang, J. J., Gatalica, Z., Philip, P. A., Shields, A. F., Lenz, H., & Marshall, J. L. (2017) · Oncotarget · doi:10.18632/oncotarget.21169 · Cited by 223
Advancing to the era of cancer immunotherapy
Wang, Y., Wang, M., Wu, H., & Xu, R. (2021) · 癌症：英文版 · doi:10.1002/cac2.12178 · Cited by 221
Cancer Neoantigens and Applications for Immunotherapy
Desrichard, A., Snyder, A., & Chan, T. A.-T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3175 · Cited by 219
Wang, D. Y., Ye, F., Zhao, S., & Johnson, D. B. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1344805 · Cited by 220
Checkpoint inhibitors in pancreatic cancer
Henriksen, A., Dyhl-Polk, A., Chen, I. M., & Nielsen, D. L. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.06.005 · Cited by 219
Ludford, K. T., Ho, W. J., Thomas, J. V., Raghav, K. P. S., Blum-Murphy, M. A., Fleming, N. D., Lee, M. S., Smaglo, B. G., You, Y. N., Tillman, M. M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01351 · Cited by 221
Wang, M., Rousseau, B., Qiu, K., Huang, G., Zhang, Y., Su, H., Bihan-Benjamin, C. L., Khati, I., Artz, O., Foote, M. B., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01957-8 · Cited by 226
Hepatocellular carcinoma in the era of immunotherapy
Sim, H., & Knox, J. J. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2017.10.007 · Cited by 216
Salem, M. E., Puccini, A., Grothey, A. F., Raghavan, D., Goldberg, R. M., Xiu, J., Korn, W. M., Weinberg, B. A., Hwang, J. J., Shields, A. F., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0735 · Cited by 220
Self-citationTemozolomide-associated hypermutation in gliomas
Choi, S., Yu, Y., Grimmer, M., Wahl, M. T., Chang, S. M., & Costello, J. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy016 · Cited by 221
Muro, K., Cutsem, E. V., Narita, Y., Pentheroudakis, G. E., Baba, E., Li, J., Ryu, M. H., Zamaniah, W. I. W., Yong, W. P., Yeh, K. H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy502 · Cited by 216
Stem-like exhausted and memory CD8+ T cells in cancer
Gebhardt, T., Park, S. L., & Parish, I. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00615-0 · Cited by 234
Weiss, G. J., Blaydorn, L., Beck, J., Bornemann-Kolatzki, K., Urnovitz, H. B., Schütz, E., & Khemka, V. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0525-1 · Cited by 218
Monogenic and polygenic determinants of sarcoma risk: an international genetic study
Ballinger, M. L., Goode, D. L., Ray-Coquard, I. L., James, P. A., Mitchell, G., Niedermayr, E., Puri, A., Schiffman, J. D., Dite, G. S., Cipponi, A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30147-4 · Cited by 223
Buder‐Bakhaya, K., & Hassel, J. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01474 · Cited by 219
Cancer immunotherapy: it’s time to better predict patients’ response
Pilard, C., Ancion, M., Delvenne, P., Jérusalem, G., Hubert, P., & Herfs, M. F. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01413-x · Cited by 224
Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer
Zeng, Y., & Jin, R. U. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.12.004 · Cited by 221
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma
Gounder, M. M., Agaram, N. P., Trabucco, S. E., Robinson, V. L., Ferraro, R., Millis, S. Z., Krishnan, A., Lee, J., Attia, S., Abida, W. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30496-0 · Cited by 221
Self-citationBecht, É., Giraldo, N. A., Germain, C., de Reyniès, A., Laurent‐Puig, P., Zucman‐Rossi, J., Dieu‐Nosjean, M., Sautès‐Fridman, C., & Fridman, W. H. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.002 · Cited by 224
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
Kaunitz, G. J., Cottrell, T. R., Lilo, M. T., Muthappan, V., Esandrio, J., Berry, S., Xu, H., Ogurtsova, A., Anders, R. A., Fischer, A. H., et al. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.64 · Cited by 216
Self-citationInflammatory Mechanisms of HCC Development
Refolo, M. G., Messa, C., Guerra, V., Carr, B. I., & D’Alessandro, R. (2020) · Cancers · doi:10.3390/cancers12030641 · Cited by 221
Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer
Goc, J., Lv, M., Bessman, N. J., Flamar, A.-L., Sahota, S., Suzuki, H., Teng, F., Putzel, G., Eberl, G., Withers, D. R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.029 · Cited by 214
Dizon, D. S., Krilov, L., Cohen, E. E. W., Gangadhar, T. C., Ganz, P. A., Hensing, T. A., Hunger, S. P., Krishnamurthi, S., Lassman, A. B., Markham, M. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.8427 · Cited by 218
Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer
Falcomatà, C., Bärthel, S., Schneider, G., Rad, R., Schmidt‐Supprian, M., & Saur, D. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0876 · Cited by 224
Dosset, M., Vargas, T. R., Lagrange, A., Boidot, R., Végran, F., Roussey, A., Chalmin, F., Dondaine, L., Paul, C., Joseph, E. L. M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433981 · Cited by 212
The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer
Palma, F. D. E. D., D’Argenio, V., Pol, J. G., Kroemer, G., Maiuri, M. C., & Salvatore, F. (2019) · Cancers · doi:10.3390/cancers11071017 · Cited by 229
Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside
Lizardo, D. Y., Kuang, C., Hao, S., Yu, J., Huang, Y., & Zhang, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188447 · Cited by 216
Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors
Roudko, V., Bozkus, C. C., Orfanelli, T., McClain, C. B., Carr, C. E., O’Donnell, T. J., Chakraborty, L., Samstein, R. M., Huang, K., Blank, S. V., et al. (2020) · Cell · doi:10.1016/j.cell.2020.11.004 · Cited by 219
The pancreatic cancer genome revisited
Hayashi, A., Hong, J., & Iacobuzio-Donahue, C. A. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00463-z · Cited by 211
Future cancer research priorities in the USA: a Lancet Oncology Commission
Jaffee, E. M., Dang, C. V., Agus, D. B., Alexander, B. M., Anderson, K. C., Ashworth, A., Barker, A. D., Bastani, R., Bhatia, S. N., Bluestone, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30698-8 · Cited by 212
An update on treatment options for pancreatic adenocarcinoma
Lambert, A., Schwarz, L., Borbath, I., Henry, A., Laethem, J. V., Malka, D., Ducreux, M. P., & Conroy, T. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919875568 · Cited by 222
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
Ai, L., Chen, J., Yan, H., He, Q., Luo, P., Xu, Z., & Yang, X. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s267433 · Cited by 217
Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy
Di Pilato, M., Kim, E. Y., Cadilha, B. L., Prüßmann, J. N., Nasrallah, M. N., Seruggia, D., Usmani, S. M., Misale, S., Zappulli, V., Carrizosa, E., et al. (2019) · Nature · doi:10.1038/s41586-019-1215-2 · Cited by 210
Allgäuer, M., Budczies, J., Christopoulos, P., Endris, V., Lier, A., Rempel, E., Volckmar, A., Kirchner, M., von Winterfeld, M., Leichsenring, J., et al. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.14 · Cited by 212
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
Wilky, B. A. (2019) · Immunological Reviews · doi:10.1111/imr.12766 · Cited by 214
Lee, J. W., Komar, C. A., Bengsch, F., Graham, K. L., & Beatty, G. L. (2016) · Current Protocols in Pharmacology · doi:10.1002/cpph.2 · Cited by 212
Self-citationPD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Grigg, C. M., & Rizvi, N. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0153-x · Cited by 219
Hypermutation In Pancreatic Cancer
Humphris, J. L., Patch, A., Nones, K., Bailey, P. J., Johns, A. L., McKay, S., Chang, D. K.-F., Miller, D. K., Pajic, M., Kassahn, K. S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.060 · Cited by 209
Self-citationImmune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Panda, A., Mehnert, J. M., Hirshfield, K. M., Riedlinger, G., Damare, S., Saunders, T., Kane, M., Sokol, L. O., Stein, M. N., Poplin, E. A., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx213 · Cited by 209
Emerging strategies for combination checkpoint modulators in cancer immunotherapy
Popović, A., Jaffee, E. M., & Zaidi, N. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120775 · Cited by 209
Immune cell - produced ROS and their impact on tumor growth and metastasis
Kennel, K. B., & Greten, F. R. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101891 · Cited by 213
Roberti, M. P., Yonekura, S., Duong, C. P. M., Picard, M., Ferrere, G., Tidjani Alou, M., Rauber, C., Iebba, V., Lehmann, C. H. K., Amon, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0882-8 · Cited by 208
Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity
Elliott, L., Doherty, G. A., Sheahan, K. D., & Ryan, E. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00086 · Cited by 219
Combination of photodynamic therapy (PDT) and anti-tumor immunity in cancer therapy
Hwang, H. S., Shin, H., Han, J., & Na, K. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0377-x · Cited by 208
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade
Nathanson, T., Ahuja, A., Rubinsteyn, A., Aksoy, B. A., Hellmann, M. D., Miao, D., Allen, E. M. V., Merghoub, T., Wolchok, J. D., Snyder, A., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0019 · Cited by 211
Current Perspectives in Cancer Immunotherapy
Christofi, T., Baritaki, S., Falzone, L., Libra, M., & Zaravinos, A. (2019) · Cancers · doi:10.3390/cancers11101472 · Cited by 209
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
Zhao, B., Zhao, H., & Zhao, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937612 · Cited by 213
Willsmore, Z. N., Coumbe, B. G. T., Crescioli, S., Reci, S., Gupta, A., Harris, R. J. C., Chenoweth, A. M., Chauhan, J., Bax, H. J., McCraw, A. J., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202048747 · Cited by 216
Cancer gene mutation frequencies for the U.S. population
Mendiratta, G., Ke, E., Aziz, M., Liarakos, D., Tong, M. M., & Stites, E. C. (2021) · Nature Communications · doi:10.1038/s41467-021-26213-y · Cited by 225
Neurologic complications of immune checkpoint inhibitors
Hottinger, A. F. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000391 · Cited by 208
Osta, B. E. E., Hu, F., Sadek, R. A., Chintalapally, R., & Tang, S. C. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.002 · Cited by 208
Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model
Schrörs, B., Boegel, S., Albrecht, C. H., Bukur, T., Bukur, V., Holtsträter, C., Ritzel, C., Manninen, K., Tadmor, A. D., Vormehr, M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01195 · Cited by 215
Resistance mechanisms to immune checkpoint inhibitors: updated insights
Al-Saafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02212-7 · Cited by 226
Looi, C.-K., Chung, F. F., Leong, C., Wong, S. F., Rosli, R., & Mai, C. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1153-8 · Cited by 209
Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future PromisePreprint
Sumanasuriya, S., & Bono, J. S. D. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030635 · Cited by 213
Adoptive T-Cell Therapy for Cancer
Yang, J. C.-H., & Rosenberg, S. A. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.006 · Cited by 208
Kim, K. H., Cho, J., Ku, B. M., Koh, J., Sun, J., Lee, S., Ahn, J. S., Cheon, J., Min, Y. J., Park, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1449 · Cited by 211
Rodrigues, D. N., Rescigno, P., Liu, D., Yuan, W., Carreira, S., Lambros, M. B. K., Seed, G., Mateo, J., Riisnaes, R., Mullane, S. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121924 · Cited by 209
Fang, W., Ma, Y., Yin, J. C., Hong, S., Zhou, H., Wang, A., Wang, F., Bao, H., Wu, X., Yang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0585 · Cited by 209
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Rahma, O. E., Yothers, G., Hong, T. S., Russell, M. M., You, Y. N., Parker, W., Jacobs, S. A., Colangelo, L. H., Lucas, P. C., Gollub, M. J., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.1683 · Cited by 208
DNA repair defects in cancer and therapeutic opportunitiesPreprint
Hopkins, J. L., Lan, L., & Zou, L. (2022) · Genes & Development · doi:10.1101/gad.349431.122 · Cited by 212
ten Hoorn, S., de Back, T. R., Sommeijer, D. W., & Vermeulen, L. (2022) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab106 · Cited by 203
Current progress in immunotherapy for pancreatic cancer
Foley, K., Kim, V., Jaffee, E. M., & Zheng, L. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.12.020 · Cited by 204
T cell exhaustion: from pathophysiological basics to tumor immunotherapy
Catakovic, K., Klieser, E., Neureiter, D., & Geisberger, R. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0160-z · Cited by 207
Applications of Immunogenomics to Cancer
Liu, X. S., & Mardis, E. R. (2017) · Cell · doi:10.1016/j.cell.2017.01.014 · Cited by 207
PD-1 Blockade in Advanced Adrenocortical Carcinoma
Raj, N. P., Zheng, Y., Kelly, V., Katz, S. S., Chou, J. F., Do, R. K. G., Capanu, M., Zamarin, D., Saltz, L. B., Ariyan, C. E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01586 · Cited by 208
Tinsley, N., Zhou, C., Tan, G., Rack, S., Lorigan, P., Blackhall, F., Krebs, M., Carter, L., Thistlethwaite, F., Graham, D., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0160 · Cited by 201
Khagi, Y., Goodman, A. M., Daniels, G. A., Patel, S. P., Sacco, A. G., Randall, J. M., Bazhenova, L. A., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1439 · Cited by 203
T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma
Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D., & Hingorani, S. R. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0322 · Cited by 206
Huang, J., Xu, B., Mo, H., Zhang, W., Chen, X., Wu, D., Qu, D., Wang, X., Lan, B., Yang, B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2439 · Cited by 201
Valle, L., Vilar, E., Tavtigian, S. V., & Stoffel, E. M. (2018) · The Journal of Pathology · doi:10.1002/path.5229 · Cited by 213
Battaglin, F., Naseem, M., Lenz, H., & Salem, M. E. (2018) · PubMed · Cited by 204
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers
Hanada, K.-I., Zhao, C., Gil-Hoyos, R., Gartner, J. J., Chow-Parmer, C., Lowery, F. J., Krishna, S., Prickett, T. D., Kivitz, S., Parkhurst, M. R., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.03.012 · Cited by 200
Koelzer, V. H., Rothschild, S. I., Zihler, D., Wicki, A., Willi, B., Willi, N., Voegeli, M., Cathomas, G., Zippelius, A., & Mertz, K. D. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0117-1 · Cited by 200
Current epidemiology of cholangiocarcinoma in Western countries
Vithayathil, M., & Khan, S. A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.022 · Cited by 200
Masucci, G. V., Cesano, A., Hawtin, R. E., Janetzki, S., Zhang, J., Kirsch, I. R., Dobbin, K. K., Alvarez, J. D., Robbins, P. B., Selvan, S. R., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0178-1 · Cited by 200
Metadata
- Authors
- Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., Biedrzycki, B., Donehower, R. C., Zaheer, A., Fisher, G. A., Crocenzi, T. S., Lee, J. J., Duffy, S. M., Goldberg, R. M., de la Chapelle, A., Koshiji, M., Bhaijee, F., Huebner, T., Hruban, R. H., Wood, L. D., Cuka, N., Pardoll, D. M., Papadopoulos, N., Kinzler, K. W., Zhou, S., Cornish, T. C., Taube, J. M., Anders, R. A., Eshleman, J. R., Vogelstein, B., & Diaz, L. A.
- Affiliations
- Swim Across America (US)
- Howard Hughes Medical Institute (US)
- Johns Hopkins University (US)
- Providence Portland Medical Center (US)
- University of Pittsburgh (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- From the Swim Across America Laboratory (D.T.L., J.N.U., B.R.B., L.A.D.), Sidney Kimmel Comprehensive Cancer Center (D.T.L., J.N.U., H.W., H.K., A.D.E., A.D.S., B.S.L., N.S.A., D.L., B.B., R.C.D., D.M.P., N.P., K.W.K., S.Z., B.V., L.A.D.), Ludwig Center and Howard Hughes Medical Institute (B.R.B., A.D.S., N.P., K.W.K., S.Z., B.V., L.A.D.), and the Departments of Radiology (A.Z.) and Pathology (F.B., T.H., R.H.H., L.D.W., N.C., T.C.C., J.M.T., R.A.A., J.R.E.), Johns Hopkins University School of Medicine,...
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Le, Dung T.
- Wang, Hao
- Bartlett, Bjarne R.
- Kemberling, Holly
- Skora, Andrew D.
- Azad, Nilofer S.
- Donehower, Ross C.
- Zaheer, Atif
- Fisher, George A.
- Crocenzi, Todd S.
- Lee, James J.
- Duffy, Steven M.
- Goldberg, Richard M.
- Bhaijee, Feriyl
- Huebner, Thomas
- Hruban, Ralph H.
- Wood, Laura D.
- Pardoll, Drew M.
- Papadopoulos, Nickolas
- Kinzler, Kenneth W.
- Zhou, Shibin
- Cornish, Toby C.
- Taube, Janis M.
- Anders, Robert A.
- Eshleman, James R.
- Vogelstein, Bert
- Diaz, Luis A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-06-25
- Volume
- 372
- Issue
- 26
- Pages
- 2509-2520
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4481136
- OpenAlex
- W1940241680
- Cited by
- 9,377
- References
- 59
- Citations by year
- 2026: 450 · 2025: 577 · 2024: 680 · 2023: 864 · 2022: 958 · 2021: 1155 · 2020: 1123 · 2019: 911 · 2018: 935 · 2017: 878 · 2016: 668 · 2015: 167
- FWCI
- 382.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA67941, CA163672, CA16058, CA 57345, CA43460, K23CA163672, U01CA067941, R37CA043460, R01CA057345, R01CA067941, P50CA062924, R37CA057345, P30CA016058, P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- anti-PD-1 therapy, pembrolizumab, mismatch repair deficiency, immune checkpoint inhibitors, somatic mutations, tumor mutational burden, colorectal cancer, metastatic carcinoma, predictive biomarkers, exome sequencing, cancer immunotherapy, progression-free survival, overall survival
- MeSH terms
- Adenocarcinoma, Adult, Aged, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Colorectal Neoplasms, Disease-Free Survival, Kaplan-Meier Estimate, DNA Mismatch Repair, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
